TransMedics Group (NASDAQ:TMDX) Shares Down 4.3% – Time to Sell?

TransMedics Group, Inc. (NASDAQ:TMDX) shares traded down 4.3% on Thursday . The stock traded as low as $58.90 and last traded at $59.29. 310,211 shares changed hands during mid-day trading, a decline of 91% from the average session volume of 3,289,978 shares. The stock had previously closed at $61.97.

Wall Street Analysts Forecast Growth

TMDX has been the subject of several research analyst reports. Canaccord Genuity Group reduced their target price on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a report on Wednesday, November 20th. Piper Sandler cut their price objective on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a research report on Wednesday, December 11th. Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a research report on Wednesday, December 11th. Oppenheimer reiterated an “outperform” rating and set a $125.00 target price on shares of TransMedics Group in a research note on Tuesday, December 3rd. Finally, Robert W. Baird reduced their price target on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a research note on Wednesday, December 11th. Three investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $122.70.

TransMedics Group Price Performance

The firm has a market cap of $2.04 billion, a P/E ratio of 64.70 and a beta of 2.12. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The company’s 50-day moving average is $69.04 and its two-hundred day moving average is $115.58.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). The firm had revenue of $108.76 million for the quarter, compared to the consensus estimate of $115.00 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The business’s revenue was up 63.7% on a year-over-year basis. During the same period last year, the company posted ($0.12) EPS. Sell-side analysts anticipate that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Insider Activity

In related news, Director Edward M. Basile sold 6,750 shares of TransMedics Group stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total transaction of $563,962.50. Following the sale, the director now directly owns 732 shares of the company’s stock, valued at approximately $61,158.60. The trade was a 90.22 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Tamer I. Khayal sold 1,084 shares of the company’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $86.40, for a total transaction of $93,657.60. Following the transaction, the insider now owns 20,843 shares of the company’s stock, valued at approximately $1,800,835.20. This represents a 4.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On TransMedics Group

Several hedge funds have recently modified their holdings of TMDX. State of Alaska Department of Revenue bought a new position in TransMedics Group in the third quarter valued at about $2,560,000. Charles Schwab Investment Management Inc. increased its stake in shares of TransMedics Group by 2.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 271,694 shares of the company’s stock valued at $42,656,000 after buying an additional 6,634 shares during the period. Zacks Investment Management bought a new position in TransMedics Group in the 3rd quarter valued at approximately $1,607,000. Vaughan Nelson Investment Management L.P. boosted its position in TransMedics Group by 24.3% during the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 329,010 shares of the company’s stock worth $51,654,000 after buying an additional 64,360 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. grew its holdings in TransMedics Group by 665.1% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 74,625 shares of the company’s stock worth $11,716,000 after acquiring an additional 64,872 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.